SEARCH

SEARCH BY CITATION

REEFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 2
    Stenzl A, Cowan NC, De Santis M, et al. Guidelines on bladder cancer: muscle-invasive and metastatic. Arnheim, The Netherlands: European Association of Urology; 2008: 56.
  • 3
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675.
  • 4
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48: 202-205.
  • 5
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866.
  • 6
    International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999; 354: 533-540.
  • 7
    Weight CJ, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Cancer. 2009; 115: 792-799.
  • 8
    Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
  • 9
    Dalbagni G, Genega E, Hashive M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001; 165: 1111-1116.
  • 10
    Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. Cancer. 2008; 113: 2471-2477.
  • 11
    Cheung YB. A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol. 2007; 166: 1337-1344.
  • 12
    Agresti A. Categorical data analysis. 2nd ed. New York: John Wiley & Sons, Inc.; 2002: 145-146, 267-314.
  • 13
    Cox D. Regression models and life tables. J Royal Stat Soc 1972; B34: 187.
  • 14
    Prentice R, Kalbfleisch J, Peterson A, Flournoy N, Farewell V, Breslow N. The analysis of failure times in the presence of competing risks. Biometrics. 1978; 34: 541-554.
  • 15
    Marubini E, Valsecchi M. Analysing survival data from clinical trials and observational studies. New York: John Wiley & Sons, Inc.; 1995: 171-181, 192, 235, 346.
  • 16
    Scosyrev E, Ely BW, Messing EM, et al. Do mixed histologic features affect survival benefit from neo-adjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? BJU Int. (In press).
  • 17
    Sonpavde G, Goldman BH, Speights VO. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: 4104-4109.
  • 18
    Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int. 2010; 106; 493-499.
  • 19
    Herr WH, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001; 165: 811-814.
  • 20
    Nieuwenhuijzen JA, Bex A, Meinhardt W, et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol. 2005; 174: 80-85.